A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Myovant Sciences's Debt-to-Equity or its related term are showing as below:
MYOV'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.59 Med: -0.78 Max: 22.93
Current: -0.76
During the past 7 years, the highest Debt-to-Equity Ratio of Myovant Sciences was 22.93. The lowest was -2.59. And the median was -0.78.
MYOV's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.12
vs MYOV: -0.76
Myovant Sciences Debt-to-Equity Historical Data
The historical data trend for Myovant Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Debt-to-Equity
1.16
22.93
-1.17
-1.04
-0.78
Myovant Sciences Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Debt-to-Equity
-0.92
-0.96
-0.85
-0.78
-0.76
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Debt-to-Equity falls into.
Myovant Sciences Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Myovant Sciences's Debt to Equity Ratio for the fiscal year that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Myovant Sciences Debt-to-Equity Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.79(4.46%) Volume: 905,404 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
